復星醫藥(02196.HK):復星醫藥產業與BioNTech就向中國大陸供應新冠疫苗產品訂立供貨協議
格隆匯 12 月 16日丨復星醫藥(02196.HK)發佈公告,有關公司附屬公司上海復星醫藥產業發展有限公司(“復星醫藥產業”)與BioNTech SE(“BioNTech”)訂立開發及許可協議,BioNTech授權復星醫藥產業在區域內獨家開發、商業化基於其專有的mRNA技術平台研發的針對COVID-19的疫苗產品(“新冠疫苗產品”)。2020年12月15日,BioNTech與復星醫藥產業訂立有關許可協議的第一號修訂協議,內容有關(其中包括)建議供應新冠疫苗產品及相關依據許可協議雙方的合作框架進展而作的更新。
同日,BioNTech Manufacturing GmbH,為BioNTech的附屬公司(“BioNTech Manufacturing”)、復星醫藥產業及BioNTech就有關BioNTech Manufacturing向其於中國大陸供應新冠疫苗產品訂立供貨協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.